So they continued the Herceptin/Avastin after the cycles of Taxotere? I wonder if survival would be improved if Herceptin or Herceptin/Avastin was continued past progression.
Not sure I'm tracking this:
Quote:
|
The regimen was generally well tolerated, including no increased risk of cardiotoxicity
|
Quote:
|
However, cardiotoxicity complicated treatment in almost 40% of the cases.
|
So...same as other treatments i.e. 40%?
I wonder if there is any data on Taxotere/Herceptin without Avastin.
"Data from correlational studies of circulating tumor cells and circulating endothelial cells will be reported at a later date"
That would be interesting.
I'd also be curious about the combo with Abraxane instead of Taxotere.